Ritter Pharmaceuticals, Inc.
1801 Century Park East
55 articles with Ritter Pharmaceuticals, Inc.
Clinical Catch-Up: September 9-13
9/16/2019Last week was a busy one for clinical trial results, particularly with the European Committee for Treatment and Research in Multiple Sclerosis 2019 Congress going on. Here’s a look at some of the top clinical trial stories.
Ritter Pharma Raises $23 Million To Fund Initiation Of Its Phase III Clinical Program In Lactose Intolerance
Ritter Pharma Prices $23,000,000 Public Offering
Ritter Pharma Announces Phase III Plans After Its End Of Phase II Meeting With FDA On RP-G28 For Lactose Intolerance
Ritter Pharma Reports Second Quarter 2017 Financial Results And Provides Business Update
Ritter Pharma Reports Further Analysis From Its Phase IIb/III Trial Results Demonstrating Significant Reductions In Lactose Intolerance Symptoms
Ritter Pharma Reports First Quarter 2017 Financial Results And Provides Business Updates
Ritter Pharma Announces Issuance Of New Patents For Its Lactose Intolerance Treatment, RP-G28, And Provides An Update On Its Path Forward Into Phase III
FDA Digests Ritter Pharma's Phase II Microbiome Data
Tiny SoCal Pharma Ritter Pharma Hails A Mid-Stage Victory After Changing The Primary Endpoint And Recalculating Data Of Lactose Intolerance Drug
Ritter Pharmaceuticals, Inc. Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Business Update
Ritter Pharmaceuticals, Inc. Announces Collaboration With University of British Columbia To Explore Development Of Microbiome Therapeutics In Environmental Enteropathy
Ritter Pharmaceuticals, Inc. To Ring Today's Nasdaq Stock Market Closing Bell To Kick-off Lactose Intolerance Awareness Month
Ritter Pharmaceuticals, Inc. Release: Company Announces Collaboration With University of Nebraska To Explore Development Of Microbiome Therapeutics In Metabolic Syndrome
Ritter Pharmaceuticals, Inc. Appoints William Merino, Ph.D., To Its Board Of Directors
Ritter Pharmaceuticals, Inc. Phase 2a Lactose Intolerance Clinical Trial Microbiome Data, Published In PNAS
Ritter Pharmaceuticals, Inc. Reports Third Quarter 2016 Financial Results And Provides Business Update
Ritter Pharmaceuticals, Inc. Prices $5,000,000 Public Offering Of Common Stock
Ritter Pharmaceuticals, Inc. Announces Proposed Public Offering Of Common Stock
Ritter Pharmaceuticals, Inc. Concludes Last Patient Visit Of Its Phase 2b/3 Clinical Trial Of RP-G28 For The Treatment Of Lactose Intolerance